Rapamycin remains the most validated longevity drug, but it isn't accessible to everyone. Here are the five best alternatives in 2026 — what they reproduce, what they don't, and how to use each.
Rapamycin is the gold standard for mTOR-targeted longevity intervention. The Interventions Testing Program has reproduced its lifespan benefit across more than a dozen mouse cohorts, and human pulse-dosing protocols have been used safely for years in private practice. But not everyone can access it. Some people lack a prescribing physician. Some have contraindications. Some live in jurisdictions where off-label rapamycin prescribing is uncommon.
This guide ranks the five best commercially available compounds that target overlapping mechanisms in 2026 — what each one does, what it doesn't, and how to think about it as a partial substitute.
Rapamycin's longevity-relevant effect is intermittent inhibition of the mTORC1 (mechanistic target of rapamycin complex 1) signaling pathway. mTORC1 integrates nutrient and growth signals; persistent activation drives anabolic processes, suppresses autophagy, and is implicated in age-related decline. Pulsing mTORC1 inhibition shifts cellular physiology toward maintenance, repair, and autophagy — the same broad direction that caloric restriction pushes.
A "rapamycin alternative" is a compound that produces some directional shift along that axis. None match rapamycin's potency, specificity, or evidence base. But several do meaningful work.
Metformin activates AMPK, the energy sensor that opposes mTOR. The downstream effects on autophagy, mitochondrial biogenesis, and cellular maintenance partially overlap with rapamycin's effects. The TAME trial (now delayed but still active) is testing whether metformin slows multiple age-related diseases in non-diabetic adults.
Pros: Cheap, generic, well-characterized 60-year safety record, prescribable by most physicians for off-label use.
Cons: Blunts exercise adaptations (Konopka et al., *Aging Cell*, 2019), can cause GI side effects, requires kidney function monitoring.
Typical longevity dose: 500 mg twice daily with meals. Don't take immediately before or after exercise.
Berberine activates AMPK through a similar mechanism to metformin and produces similar improvements in glucose handling, lipid profile, and inflammatory markers. It's available without a prescription as a dietary supplement.
Pros: Available without prescription, similar mechanism to metformin, affordable.
Cons: Lower potency than metformin per mg, GI side effects, drug interactions (CYP3A4 inhibition).
Typical dose: 500 mg three times daily with meals (1500 mg total). See our berberine buyer's guide for brand selection.
Spermidine induces autophagy independently of mTOR through TFEB activation. It is the most-studied dietary autophagy inducer with both observational human data (Austrian cohort: higher spermidine intake associated with reduced mortality) and small RCT evidence for cardiovascular and cognitive benefit.
Pros: Available as a supplement, food sources (wheat germ, aged cheese, soybeans), excellent safety profile.
Cons: Modest effect size, low bioavailability of supplemental forms, no direct lifespan trial in humans.
Typical dose: 1–5 mg daily.
Acarbose blunts post-meal glucose spikes by inhibiting alpha-glucosidase. The ITP showed acarbose extends lifespan in male mice, especially when combined with rapamycin. It functions as a partial caloric restriction mimetic by reducing the rate at which carbohydrates are absorbed.
Pros: Pharmacologically distinct mechanism from AMPK or mTOR, complementary to rapamycin, prescribable.
Cons: GI flatulence in many users, requires prescription, modest effect when used alone.
Typical longevity dose: 25–50 mg with each carbohydrate-containing meal.
The most evidence-supported approach for people without rapamycin access is stacking partial mechanisms: time-restricted eating to lower baseline mTOR activation, berberine to engage AMPK, and spermidine to drive autophagy. None reproduces rapamycin individually, but in combination they hit overlapping pathways and each has independent supportive evidence.
Several heavily marketed compounds are not credible rapamycin alternatives:
| Compound | Monthly Cost (USD) | Mechanism Overlap | Evidence Quality |
| --- | --- | --- | --- |
| Metformin | $10–30 | High (AMPK) | Strong epidemiology, TAME pending |
| Berberine | $15–40 | High (AMPK) | Multiple small RCTs |
| Spermidine | $25–60 | Moderate (autophagy) | Observational + small RCTs |
| Acarbose | $30–60 | Moderate (glucose) | ITP mouse data, observational human |
| Combo stack | $50–120 | Combined | Each component supported |
For more on rapamycin itself, see Rapamycin: The Most Promising Longevity Drug? and our 2026 dosing protocol guide. For the broader longevity drug landscape, see Longevity Drugs in 2026: Metformin, Rapamycin, and Beyond.
Can I just stack everything?
No. Drug interactions matter. Berberine + metformin together can cause significant GI upset and excessive blood sugar lowering. Acarbose + metformin is reasonable but requires monitoring. Discuss combinations with a prescribing physician.
Is any single supplement as good as rapamycin?
No. Rapamycin is in a different evidence tier — single mechanism, replicated lifespan extension across cohorts. Supplements engage overlapping pathways less potently and with less evidence.
Will these alternatives extend my life?
The honest answer: no one knows. The mouse data is supportive for several. The human data is suggestive for metformin and observational for spermidine. Use them as part of a broader healthspan strategy, not as a guarantee.